Cytokine traps: multi-component, high-affinity blockers of cytokine action

Cytokines can initiate and perpetuate human diseases, and are among the best-validated of therapeutic targets. Cytokines can be blocked by the use of soluble receptors; however, the use of this approach for cytokines such as interleukin (IL)-1, IL-4, IL-6 and IL-13 that use multi-component receptor systems is limited because monomeric soluble receptors generally exhibit low affinity or function as agonists. We describe here a generally applicable method to create very high-affinity blockers called 'cytokine traps' consisting of fusions between the constant region of IgG and the extracellular domains of two distinct cytokine receptor components involved in binding the cytokine. Traps potently block cytokines in vitro and in vivo and represent a substantial advance in creating novel therapeutic candidates for cytokine-driven diseases.

[1]  D. Lindell,et al.  IL‐4 induced leucocyte trafficking in cynomolgus monkeys: correlation with expression of adhesion molecules and chemokine generation , 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[2]  B. Klein,et al.  Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. , 1995, Blood.

[3]  C. Bertrand,et al.  Interleukin-4 is required for the induction of lung Th2 mucosal immunity. , 1995, American journal of respiratory cell and molecular biology.

[4]  P. Wooley,et al.  The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. , 1993, Arthritis and rheumatism.

[5]  G. Cieslewicz,et al.  The late, but not early, asthmatic response is dependent on IL-5 and correlates with eosinophil infiltration. , 1999, The Journal of clinical investigation.

[6]  Stanley B. Cohen,et al.  Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[7]  W. Busse,et al.  Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. , 2001, The Journal of allergy and clinical immunology.

[8]  D B Corry,et al.  Requirement for IL-13 independently of IL-4 in experimental asthma. , 1998, Science.

[9]  D D Donaldson,et al.  Interleukin-13: central mediator of allergic asthma , 1998 .

[10]  L. Borish,et al.  Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. , 1999, American journal of respiratory and critical care medicine.

[11]  M. Wills-Karp.  Immunologic basis of antigen-induced airway hyperresponsiveness. , 1999, Annual review of immunology.

[12]  M. Goldenberg,et al.  Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. , 1999, Clinical therapeutics.

[13]  L. Joosten,et al.  Amelioration of established murine collagen‐induced arthritis with anti‐IL‐1 treatment , 1994, Clinical and experimental immunology.

[14]  J. Foote,et al.  Kinetic and affinity limits on antibodies produced during immune responses. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Ghrayeb,et al.  Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. , 1993, Arthritis and rheumatism.

[16]  B. Klein,et al.  Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. , 1994, The New England journal of medicine.

[17]  L. Joosten,et al.  Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra. , 1996 .

[18]  G. Campion,et al.  Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. , 1996, Arthritis and rheumatism.

[19]  T. Hirano,et al.  Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 , 1989, Cell.

[20]  Reimers Ji.  Interleukin-1 beta induced transient diabetes mellitus in rats. A model of the initial events in the pathogenesis of insulin-dependent diabetes mellitus? , 1998 .

[21]  Z Domljan,et al.  Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. , 1998, Arthritis and rheumatism.

[22]  C A Smith,et al.  Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.

[23]  N. Stahl,et al.  General mechanisms of cytokine receptor signaling. , 1998, Advances in protein chemistry.

[24]  S. Wallach,et al.  Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 1999, Arthritis and rheumatism.

[25]  A. Fischer,et al.  Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. , 2001, Blood.

[26]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[28]  Eugene S. Kim,et al.  Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[29]  W. B. Berg.  Joint inflammation and cartilage destruction may occur uncoupled , 2004, Springer Seminars in Immunopathology.

[30]  B. Klein,et al.  Human anti‐mouse antibody response to the injection of murine monoclonal antibodies against IL‐6 , 1994, Clinical and experimental immunology.

[31]  G. Yancopoulos,et al.  LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. , 1993, Science.

[32]  G. Yancopoulos,et al.  The alphas, betas, and kinases of cytokine receptor complexes , 1993, Cell.

[33]  S. V. van Deventer.  Anti-TNF antibody treatment of Crohn's disease , 1999, Annals of the rheumatic diseases.

[34]  M. Helsen,et al.  Accelerated onset of collagen‐induced arthritis by remote inflammation , 1994, Clinical and experimental immunology.